PCRX — Pacira BioSciences, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on PCRX
| date | signal | measured base rate |
|---|---|---|
| 2026-08-06 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-08-04 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-08-03 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-07-28 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-28 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-06-24 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-17 | SLONIN JONATHAN Chief Medical Officer | Open-market sale 10b5-1 plan | 3.0K | 23.23 | 70.6K |
| 2026-06-11 | RIKER LAUREN Senior Vice President, Finance | Open-market sale 10b5-1 plan | 6.1K | 23.50 | 143.7K |
| 2026-06-10 | Brege Laura Director | Grant or award | 6.4K | 0.00 | 0 |
| 2026-06-10 | CHRISTIE CHRISTOPHER Director | Grant or award | 6.4K | 0.00 | 0 |
| 2026-06-10 | Hirawat Samit Director | Grant or award | 6.4K | 0.00 | 0 |
| 2026-06-10 | YANG MICHAEL J. Director | Grant or award | 6.4K | 0.00 | 0 |
| 2026-06-10 | Young Alethia Director | Grant or award | 6.4K | 0.00 | 0 |
| 2026-06-10 | BIGAL MARCELO Director | Grant or award | 6.4K | 0.00 | 0 |
| 2026-06-10 | Froimson Mark Director | Grant or award | 6.4K | 0.00 | 0 |
| 2026-06-04 | WILLIAMS KRISTEN Chief Administrative Officer | Open-market sale 10b5-1 plan | 10.3K | 22.27 | 228.5K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 152.2M | 6.7M |
| Doma Perpetual Capital Management LLC | 62.8M | 2.8M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 56.5M | 2.5M |
| DIMENSIONAL FUND ADVISORS LP | 46.6M | 2.1M |
| D. E. Shaw & Co., Inc. | 44.8M | 2.0M |
| STATE STREET CORP | 43.4M | 1.9M |
| RENAISSANCE TECHNOLOGIES LLC | 41.3M | 1.8M |
| VANGUARD CAPITAL MANAGEMENT LLC | 40.3M | 1.8M |
| GOLDMAN SACHS GROUP INC | 35.5M | 1.6M |
| MORGAN STANLEY | 31.5M | 1.4M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about PCRX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →